Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China

Table 3 Baseline characteristics of hepatitis C virus patients based on severity of liver disease

	Non-cirrhosis (n = 212)	Cirrhosis (compensated and decompensated) (n = 154)	P value
Age (yr)	48.5 ± 12.6	57.3 ± 8.9	< 0.001
Gender (males, %)	115 (54.2)	77 (50.0)	0.423
TBil (µmol/L)	15.04 ± 8.78	25.95 ± 9.59	< 0.001
ALT (U/L)	41.74 ± 43.00	64.88 ± 44.81	0.029
AST (U/L)	31.47 ± 26.67	68.12 ± 43.44	0.034
Albumin (g/L)	44.5 ± 4.5	33.0 ± 8.6	< 0.001
TCHO (mmol/L)	3.86 ± 0.55	3.82 ± 0.66	0.349
Hemoglobin (mg/dL)	135.3 ± 10.6	99.5 ± 20.4	0.002
Platelets (109/L)	195.3 ± 59.8	86.1 ± 32.2	< 0.001
AFP (ng/mL)	4.04 ± 1.79	5.58 ± 8.61	0.045
Log10 HCV RNA (IU/mL)	6.6 ± 0.8	6.3 ± 1.3	0.040
LSM (kPa)	5.71 ± 1.7	10.26 ± 5.1	< 0.001
Fibrosis 4 score	1.43 ± 1.0	7.49 ± 6.0	< 0.001
APRI	1.06 ± 0.9	2.3 ± 1.5	< 0.001

TBil: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TCHO: Total cholesterol; AFP: Alpha fetoprotein; LSM: Liver stiffness measurement; APRI: AST-to-platelet ratio index.